SG11201901355SA - Methods of treating severe insulin resistance by interfering with glucagon receptor signaling - Google Patents
Methods of treating severe insulin resistance by interfering with glucagon receptor signalingInfo
- Publication number
- SG11201901355SA SG11201901355SA SG11201901355SA SG11201901355SA SG11201901355SA SG 11201901355S A SG11201901355S A SG 11201901355SA SG 11201901355S A SG11201901355S A SG 11201901355SA SG 11201901355S A SG11201901355S A SG 11201901355SA SG 11201901355S A SG11201901355S A SG 11201901355SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tarrytown
- insulin resistance
- severe insulin
- new york
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Zoology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662381263P | 2016-08-30 | 2016-08-30 | |
US201662411032P | 2016-10-21 | 2016-10-21 | |
PCT/US2017/049137 WO2018044903A1 (fr) | 2016-08-30 | 2017-08-29 | Procédés de traitement de la résistance à l'insuline grave par interférence avec la signalisation du récepteur du glucagon |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901355SA true SG11201901355SA (en) | 2019-03-28 |
Family
ID=59799505
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901355SA SG11201901355SA (en) | 2016-08-30 | 2017-08-29 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
SG10201913074WA SG10201913074WA (en) | 2016-08-30 | 2017-08-29 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913074WA SG10201913074WA (en) | 2016-08-30 | 2017-08-29 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
Country Status (11)
Country | Link |
---|---|
US (3) | US10995146B2 (fr) |
EP (1) | EP3506940A1 (fr) |
JP (2) | JP7173962B2 (fr) |
KR (2) | KR20190044079A (fr) |
CN (1) | CN109922831A (fr) |
AU (1) | AU2017321423A1 (fr) |
CA (1) | CA3034777A1 (fr) |
MA (1) | MA46089A (fr) |
MX (2) | MX2019002437A (fr) |
SG (2) | SG11201901355SA (fr) |
WO (1) | WO2018044903A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019002437A (es) | 2016-08-30 | 2019-10-09 | Regeneron Pharma | Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon. |
CN110357959B (zh) * | 2018-04-10 | 2023-02-28 | 鸿运华宁(杭州)生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
CN113481290B (zh) * | 2021-06-30 | 2022-08-23 | 华南农业大学 | 一种klf4基因在制备检测和/或减少母鼠不良妊娠结局的产品中的应用 |
CN114342875A (zh) * | 2022-01-12 | 2022-04-15 | 吉林大学 | 一种新型妊娠糖尿病动物模型的建立方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5836308B2 (ja) | 1977-02-10 | 1983-08-08 | 大塚製薬株式会社 | 抗体の製造方法 |
US4206199A (en) | 1977-07-22 | 1980-06-03 | Takeda Chemical Industries, Ltd. | Novel glucagon fragment and its derivatives |
JPS56163456A (en) | 1980-05-21 | 1981-12-16 | Otsuka Pharmaceut Co Ltd | Preparation of antigen |
US4423034A (en) | 1980-10-16 | 1983-12-27 | Toyo Jozo Kabushiki Kaisha | Process for the preparation of antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
CA2142819C (fr) | 1992-08-28 | 2003-08-19 | Wayne R. Kindsvogel | Recepteurs du glucagon |
JP2729159B2 (ja) | 1994-10-31 | 1998-03-18 | 日清製粉株式会社 | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
JP2007514794A (ja) | 2003-12-19 | 2007-06-07 | メルク エンド カムパニー インコーポレーテッド | 環式グアニジン、そのような化合物を含む組成、及び使用方法 |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
AU2005252183B2 (en) | 2004-06-04 | 2008-07-17 | Merck Sharp & Dohme Corp. | Pyrazole derivatives, compositions containing such compounds and methods of use |
DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
JP2008505905A (ja) | 2004-07-07 | 2008-02-28 | メルク エンド カムパニー インコーポレーテッド | ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法 |
CN1993124A (zh) | 2004-07-22 | 2007-07-04 | 默克公司 | 取代吡唑、含有这种化合物的组合物及其应用 |
SI1856090T1 (sl) | 2005-02-11 | 2010-02-26 | Lilly Co Eli | Substituirani derivati tiofena kot antagonisti glukagonskega receptorja, priprava in terapevtske uporabe |
WO2006102067A1 (fr) | 2005-03-21 | 2006-09-28 | Merck & Co., Inc. | Derives d'aryle et d'heteroaryle substitues |
WO2006104826A2 (fr) | 2005-03-30 | 2006-10-05 | Merck & Co., Inc. | Composes antagonistes du recepteur du glucagon, compositions renfermant de tels composes et methodes d'utilisation |
AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
AU2007240315A1 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | GLP-1 compound/glucagon antibody compositions |
CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
ES2494294T3 (es) | 2007-02-09 | 2014-09-15 | Metabasis Therapeutics, Inc. | Antagonistas del receptor de glucagón |
CL2009000586A1 (es) | 2008-03-27 | 2010-06-04 | Lilly Co Eli | Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso |
WO2009140342A1 (fr) | 2008-05-16 | 2009-11-19 | Schering Corporation | Antagonistes du récepteur de glucagon, compostions et procédé d'utilisation de ces composés |
WO2010030722A1 (fr) | 2008-09-15 | 2010-03-18 | Merck Sharp & Dohme Corp. | Composés antagonistes du récepteur du glucagon, compositions contenant ces composés et méthodes d'utilisation |
US8445538B2 (en) | 2008-12-19 | 2013-05-21 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
US20110281795A1 (en) | 2009-01-28 | 2011-11-17 | Songnian Lin | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
WO2010093535A1 (fr) | 2009-02-12 | 2010-08-19 | Merck Sharp & Dohme Corp. | Composés antagonistes de récepteur de glucagon, compositions contenant ces composés et procédés d'utilisation |
US8809579B2 (en) | 2009-02-13 | 2014-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | 3−(4−置換アルキル−フェニル)−2−フランカルボン酸誘導体およびその薬学的に許容される塩 |
JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
EP3401401B1 (fr) | 2011-09-20 | 2020-04-15 | Ionis Pharmaceuticals, Inc. | Modulation anti-sens d'expression gcgr |
US9453073B2 (en) | 2011-12-02 | 2016-09-27 | Eli Lilly And Company | Anti-glucagon antibodies and uses thereof |
US9248189B2 (en) | 2013-05-07 | 2016-02-02 | Pfizer Inc. | Anti-glucagon receptor antibodies and pharmaceutical compositions thereof |
SG11201701711VA (en) | 2014-09-16 | 2017-04-27 | Regeneron Pharma | Anti-glucagon antibodies and uses thereof |
MX2019002437A (es) | 2016-08-30 | 2019-10-09 | Regeneron Pharma | Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon. |
-
2017
- 2017-08-29 MX MX2019002437A patent/MX2019002437A/es unknown
- 2017-08-29 CN CN201780065987.7A patent/CN109922831A/zh active Pending
- 2017-08-29 MA MA046089A patent/MA46089A/fr unknown
- 2017-08-29 KR KR1020197008021A patent/KR20190044079A/ko not_active IP Right Cessation
- 2017-08-29 SG SG11201901355SA patent/SG11201901355SA/en unknown
- 2017-08-29 EP EP17762315.4A patent/EP3506940A1/fr active Pending
- 2017-08-29 CA CA3034777A patent/CA3034777A1/fr active Pending
- 2017-08-29 WO PCT/US2017/049137 patent/WO2018044903A1/fr unknown
- 2017-08-29 SG SG10201913074WA patent/SG10201913074WA/en unknown
- 2017-08-29 KR KR1020237014250A patent/KR20230062673A/ko not_active Application Discontinuation
- 2017-08-29 US US16/328,935 patent/US10995146B2/en active Active
- 2017-08-29 AU AU2017321423A patent/AU2017321423A1/en active Pending
- 2017-08-29 JP JP2019511610A patent/JP7173962B2/ja active Active
-
2019
- 2019-02-28 MX MX2021006457A patent/MX2021006457A/es unknown
-
2021
- 2021-04-05 US US17/222,236 patent/US11708416B2/en active Active
-
2022
- 2022-08-01 JP JP2022122568A patent/JP2022140605A/ja active Pending
-
2023
- 2023-06-05 US US18/329,358 patent/US20230416384A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2021006457A (es) | 2021-07-02 |
WO2018044903A1 (fr) | 2018-03-08 |
JP2019528306A (ja) | 2019-10-10 |
SG10201913074WA (en) | 2020-03-30 |
US11708416B2 (en) | 2023-07-25 |
US20190218301A1 (en) | 2019-07-18 |
US20210221896A1 (en) | 2021-07-22 |
US20230416384A1 (en) | 2023-12-28 |
JP7173962B2 (ja) | 2022-11-16 |
MX2019002437A (es) | 2019-10-09 |
MA46089A (fr) | 2019-07-10 |
KR20190044079A (ko) | 2019-04-29 |
AU2017321423A1 (en) | 2019-03-14 |
RU2019107807A3 (fr) | 2021-05-18 |
KR20230062673A (ko) | 2023-05-09 |
CA3034777A1 (fr) | 2018-03-08 |
CN109922831A (zh) | 2019-06-21 |
EP3506940A1 (fr) | 2019-07-10 |
US10995146B2 (en) | 2021-05-04 |
RU2019107807A (ru) | 2020-10-01 |
JP2022140605A (ja) | 2022-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901355SA (en) | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling | |
SG11201806992VA (en) | Antibodies to tigit | |
SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201907922PA (en) | Cd19 compositions and methods for immunotherapy | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201900596XA (en) | Cannabis composition | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201900501RA (en) | Cannabis composition | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201900154VA (en) | Compounds, compositions, and methods for the treatment of disease | |
SG11201908796XA (en) | Improved antigen binding receptors | |
SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
SG11201407548UA (en) | Treatment of amd using aav sflt-1 | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201805579SA (en) | Recombinant igg fc multimers | |
SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells |